Clinical Trial Update: Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

Phase II trial evaluating alemtuzumab with DA-EPOCH-R in relapsed or refractory Hodgkin lymphoma and diffuse large B-cell lymphoma has completed; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• DA-EPOCH-R
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-10-06